Moreover, in a poly-pharmacology strategy, dual inhibitors of PTP1B and AKR1B1 could be used as multitarget drugs to treat both conditions of insulin resistance and chronic complications associated with T2DM [14]. Here, AKR1B1 is linked to Insulin resistance.